All In Biotech

Free tool

FAERS Monitor: Asparlas

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming BLA 761102 or its brand name (Asparlas, Calaspargase Pegol-Mknl). Reports on generic versions are filed under their own applications.

Reports

804

Serious

736

92% of reports

Hospitalization

340

Death reported

65

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • hypersensitivity211
  • anaphylactic reaction103
  • febrile neutropenia71
  • pancreatitis71
  • infusion related reaction67
  • hypertriglyceridaemia56
  • vomiting36
  • tachycardia28
  • neutropenia26
  • pancytopenia25
  • cough23
  • hyperglycaemia23
  • nausea23
  • sepsis21
  • hepatotoxicity20

Reports by year received

View as table
YearReports
20225
2023187
2024284
2025158
2026170

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,355 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
hypertriglyceridaemiaSignal56252.7196.013,658
anaphylactic reactionSignal10348.940.84,784
pancreatitisSignal7135.228.22,327
hypersensitivitySignal21129.826.55,883
febrile neutropeniaSignal7128.022.41,828
infusion related reactionSignal6726.521.01,620
hepatotoxicitySignal2023.515.3409
hyperglycaemiaSignal2316.511.0320
pancytopeniaSignal2511.78.0235
tachycardiaSignal288.25.7172
neutropeniaSignal265.03.480
sepsisSignal214.93.262
coughSignal232.11.413
vomitingSignal362.01.517
nausea230.80.52

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.